Drugs / AZD1386
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT00945178 | Aug → Sep 2009 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00832169 | Jan → Feb 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00711048 | Jun 2008 → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00714337 | Jun → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00736658 | Jun → Sep 2008 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00690079 | Feb → Oct 2008 | chronic pain syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00692146 | Jan → May 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT01019928 | Nov 2009 → Jan 2011 | esophageal disorder | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT00976534 | Sep 2009 → Feb 2010 | neuropathy, painful | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT00878501 | Mar → Jul 2009 | — | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT00672646 | Apr → Jun 2008 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD1386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00711048 ↗ |
| Action | Inhibit | “AIM: To investigate the effect of a TRPV1 antagonist (AZD1386) on experimentally induced oesophageal pain.” PMID 21410733 ↗ Mar 2011 |
| Modality | Small molecule | — CHEMBL3545039 ↗ |
| Route | Oral | “95mg, oral solution, single dose” NCT00672646 ↗ |
| Target | TRPV1 | “TRPV1 antagonist AZD1386” PMID 23320520 ↗ Jan 2013 |